WHO ICTRP trial
Quimi-Hib® and Quimi-Hib(AlPO4) vaccines in an accelerated 6-10-14 weeks primary…
RPCEC00000135 · Registro Público Cubano de Ensayos Clínicos (RPCEC) · Not Recruiting
Key facts
| Trial ID | RPCEC00000135 |
|---|---|
| Public title | Quimi-Hib® and Quimi-Hib(AlPO4) vaccines in an accelerated 6-10-14 weeks primary vaccination series |
| Scientific title | “Immunogenicity, tolerance and reactogenicity of Quimi-Hib and alum phospate adjuvanted Quimi-Hib vaccines in healthy infants according to 6 – 10 – 14 weeks primary vaccination series. A multicenter, controlled, randomized, doubled blind clinical trial.” |
| Primary sponsor | Center for Genetic Engineering and Biotechnology |
| Secondary sponsors | Ministry of Public Health, CUBA |
| Registry | Registro Público Cubano de Ensayos Clínicos (RPCEC) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | Cuba |
| Conditions | Haemophilus influenzae type b infection prophylaxis |
| Interventions | Group I (Experimental): alum phosphate adjuvanted Quimi-Hib, 10µg, intramuscular route, 6-10-14 weeks schedule Group II (Control): Quimi-Hib, 10µg, intramuscular route, 6-10-14 weeks schedule |
| Registration date | Dec 9, 2012 |
| Target size | 208 |
| Secondary IDs | IG/QHI/SE/1001 |
| Registry page | rpcec.sld.cu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: